Kathryn Weston Clerici

Associate

Boston

+1 617 570 1363

Kathryn Clerici is an associate in Goodwin’s nationally recognized Life Sciences group, counseling clients in the industries of biotechnology and pharmaceuticals. Kathryn works with companies throughout the full range of the corporate life cycle. She represents clients in initial public offerings and capital markets transactions, startup and formation matters, venture capital financings, mergers and acquisitions, and other complex transactions. She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance and corporate governance matters.

Experience

Kathryn’s recent client representations include:

Rapport Therapeutics in connection with day-to-day governance and reporting matters, and its $174.4 million initial public offering and concurrent private placement
BeiGene in connection with day-to-day governance and reporting matters, its $3.5 billion initial public offering on STAR Market of the Shanghai Stock Exchange in China, and its $2.08 billion registered direct offering
Aerovate Therapeutics in connection with day-to-day governance and reporting matters, its $139.8 million initial public offering, and its “at-the-market” program
Adicet Bio (formerly resTORbio) in connection with day-to-day governance and reporting matters, the merger between Adicet Bio and resTORbio, its “at-the-market” programs, and multiple follow-on offerings and private placement
Cullinan Oncology in its $287.4 million initial public offering
Forma Therapeutics in connection with its $319.3 million initial public offering, $275.8 million follow-on public offering, “at-the-market” program, and $1.1 billion sale to Novo Nordisk
Theseus Pharmaceuticals, Inc. in its definitive acquisition by Concentra Biosciences, LLC
Black Diamond in the spinout of Launchpad Therapeutics
Alkermes Pharmaceuticals in the spin-off of its oncology business into Mural Oncology
LumiraDx in its merger with CA Healthcare Acquisition Corp and listing on Nasdaq
Absci Corporation in its $86.4 million follow-on offering
Avadel Pharmaceuticals in its $125 million follow-on offering, “at-the-market” program, and $65 million private placement
bluebird bio in its $575 million follow-on offering
Argenx NV in its $557 million follow-on offering
Slack in its acquisition by Salesforce
The underwriters in Acrivon Therapeutics’ $99.4 million initial public offering and concurrent private placement
The underwriters in IBEX’s $90.5 million initial public offering
The underwriters in Pandion Therapeutics’ $135 million initial public offering

Triveni Bio (formerly Amagma Therapeutics) in connection with day-to-day governance, its $92 million Series A financing, and its $115 million Series B financing
Sail Bio (formerly LARONDE) in connection with day-to-day governance, its $440 million Series B financing, and its merger with Senda Biosciences
Repertoire Immune Medicines in its $189 million Series B financing
Forma Therapeutics in its $100 million Series D financing
AsclepiX Therapeutics in its $35 million Series A financing

Professional Activities

Kathryn is a member of the Boston Bar Association.

Professional Experience

While attending law school, Kathryn worked as a corporate summer associate at Goodwin and a litigation summer associate at LibbyHoopes, P.C. in Boston. She was also an executive senior editor and a staff writer for the Boston College Law Review.

Kathryn Weston Clerici

Experience

Professional Activities

Professional Experience

Credentials

Education

JD2019

BArts&Sc2016

Admissions

Bars

Related Content

Goodwin Advises Rapport Therapeutics on Closing of $250 Million Public Offering

Goodwin Guides BeOne Medicines in IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Aerovate Therapeutics to Combine with Jade Biosciences in All-Stock Transaction

Goodwin Advises Upstream Bio on $293 Million Upsized Initial Public Offering

Goodwin Advises MBX Biosciences in Upsized Initial Public Offering

Rapport Therapeutics Completes $174.4 Millon Initial Public Offering and Concurrent Private Placement

Absci Corporation Closes $86.4 Million Follow-On Offering

Alkermes Completes Separation of Oncology Business

Kathryn Weston Clerici

Experience

Public Company Representation and Capital Markets Transactions

Private Company Representation and Significant Transactions

Professional Activities

Professional Experience

Credentials

Education

JD2019

BArts&Sc2016

Admissions

Bars

Related Content

Goodwin Advises Rapport Therapeutics on Closing of $250 Million Public Offering

Goodwin Guides BeOne Medicines in IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Aerovate Therapeutics to Combine with Jade Biosciences in All-Stock Transaction

Goodwin Advises Upstream Bio on $293 Million Upsized Initial Public Offering

Goodwin Advises MBX Biosciences in Upsized Initial Public Offering

Rapport Therapeutics Completes $174.4 Millon Initial Public Offering and Concurrent Private Placement

Absci Corporation Closes $86.4 Million Follow-On Offering

Alkermes Completes Separation of Oncology Business